Employer Oncology Roundtable Module 3: Wednesday, December 1, 2021

SURVIVORSHIP, SURVEILLANCE & BACK TO WORK









Roundtable Background

Why We Are Here

- Cancer is a top concern of employers
 - Enormous healthcare cost
 - Complex disease
 - Impacts all aspects of patient's life





Roundtable Background


Why We Are Here *(continued)*

- Serious diagnosis dissuades traditional cost containment strategies
 - Rapidly escalating costs push purchasers to be better informed
 - How to best address challenges & issues
- Employers are encouraged to play a pivotal role
 - Advances in science of cancer care progressing quickly
 - Tools needed by health plans and purchasers lagging






LVBCH – Cancer Medical Spend





LVBCH – Cancer Pharmacy Spend





Roundtable Background

National Alliance of Healthcare Purchaser Coalitions (the National Alliance)

- 2019 Achieving Value in Cancer Care Report released
 - Highlighted the need for education
 - Purchaser-Health Plan collaboration can increase value of cancer care
- 2021 Employer Oncology Roundtable Grant received by LVBCH
 - Curriculum to support employers to ask the right questions and learn the right answers to support enhancement of overall healthcare strategy





Curriculum Learning Modules




Prevention & Preliminary Diagnosis

Diagnosis, Treatment Planning & Care

Survivorship, Surveillance & Back to Work

Need for patient & caregiver psychosocial support, coordination, accommodation & benefits education across the journey


Across the Cancer Patient Journey



Employer and Psychosocial Support including Workplace Accommodation, Coordination of Services and Benefits

Module 3

Survivorship, Surveillance, and Back-to-Work



ACTION STEPS FOR EMPLOYERS:

- Promote advance care planning.
- Cover and promote palliative and hospice care.
- Support cancer survivors.
- Address demands on employees who are caregivers.
- Monitor payment reform.
- Learn from COVID-19.

Agenda

Module 3: Discussion Items

- Advanced Care Planning
 - Health Care Wishes, Palliative Care, Hospice
- Survivorship, Surveillance & Return-to-Work
 - Support at Work, Caregiving
- Update on Hot Topics
 - Payment Reform, Impact of COVID-19



Guest Experts:



Amanda Buss

Cancer Support Community Greater Lehigh Valley

Mark Wendling, мD Lehigh Valley Health Network





Melissa Wilson, MD, PhD St. Luke's University Health Network

Ellen Roth Genentech

Employers for Healthcare Value Since 1980

POLL THE AUDIENCE

1) Employer Size – How many employees does your organization employ?

- **Less than 500 employees**
- **500-999** employees
- **1,000-4,999** employees
- **□**5,000 or more employees





Advanced Care Planning

Advance Care Planning

Most Should be Addressed at the Start of the Journey, if not Before

"Advance care planning" is making decisions in advance about how to deal with a medical crisis and includes:

- Advance Directive
- Medical Power of Attorney (or Health Care Proxy)
- Durable Power of Attorney

Value increases if plan is in place *before* any cancer or non-cancer treatments

- Difficult to make decisions in the stress of the moment
- Ensures adherence to individual preferences
- Can relieve family of difficult decisions

ADVANCE DIRECTIVE a written statement of a person's wishes regarding medical treatment, often including a living will

MEDICAL POWER OF ATTORNEY/HEALTH CARE PROXY: a document in which an individual designates another person to make health care decisions if he or she is rendered incapable of making their wishes known

DURABLE POWER OF ATTORNEY: a document that allows an individual to make bank transactions, sign Social Security checks, apply for disability, or simply write checks to pay the utility bill while an individual is medically incapacitated



Advance Care Planning

Studies Show it's Often Deferred Too Long

- Only 1/3 of those < age 45 had some form of legal document in place
- Among those aged >45, between 29% and 46% had not completed even one
- Respondents from all age groups had widespread misconceptions about palliative and hospice care

Source: CancerCare Patient Access and Engagement Report. New York: CancerCare; 2016, p.9 When to re-examine your health care wishes:

- 1. Start of a new decade of life
- 2. A loved one dies
- 3. Divorce or other family upheaval
- 4. A serious diagnosis
- 5. Significant decline in health condition
- 6. Move to a new residence or someone moves in with you

Source: American Bar Association, Commission on Law and Aging, Tool Kit for Health Care Advance Planning



PATIENT RESOURCES

Remind Employees When They Should Re-examine their Healthcare Wishes

- 1. At the start of a new decade of life.
- 2. When a loved one dies.
- 3. During divorce or other family upheaval.
- 4. After receiving a serious diagnosis.

- 5. When a health condition causes significant decline.
- 6. When moving to a new residence or when someone joins the household.

Source: American Bar Association Commission on Law & Aging, *Tool Kit for Health Care* Advance Planning



Advance Care Planning

The Institute of Medicine found Wide Variations in Individual Wishes

- African Americans are less likely than white non-Hispanics to express any treatment wishes or to have written advance care planning documents.
- White Protestants (72%), Catholics (65%), and Evangelicals (62%) would stop medical treatment if they had an incurable disease and were suffering a great deal of pain
- Most black Protestants (61%) and Hispanic Catholics (57%), wanted their physician to "do everything possible to save their lives"
- More than 81% of U.S. patients with head and neck cancers wanted to hear the diagnosis alone, but patients from family-centered cultures (e.g., Japanese) more likely want a relative present
- Most (84%) of Latinos aged 60+ from L.A. would prefer care focused on relieving pain and discomfort if they became seriously ill, yet nearly half (47%) had never discussed these preferences with either their family or their physicians

Source: National Academy of Sciences. All rights reserved. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life, 148-154 (2015)



WHAT PURCHASERS SHOULD DO

Advance Care Planning

Educate entire workforce (not just cancer patients)

- Explain what it is
- Raise awareness of importance
- Make resource materials available
- Identify/refer to local resources
- Recognize differences across populations

Potential sources of assistance

- HR
- EAP
- PCP, hospital, other providers
- Attorneys, consumer organizations

Advance Care Planning Resources

AARP

https://www.aarp.org/caregiving/financial-legal/freeprintable-advance-directives/

American Bar Association

https://www.americanbar.org/groups/law_aging/resources/ health_care_decision_making/consumer_s_toolkit_for_heal th_care_advance_planning/

Cancer Support Community https://www.cancersupportcommunity.org/radio-show/spotlightmetastatic-breast-cancer-advanced-care-planning

National Hospice and Palliative Care Organization https://www.nhpco.org/



POLL THE AUDIENCE

2) Advance Care Planning – Which of the following does your organization have in place?

Advance Care Planning education to all employees

HR available to assist, answer questions

QRelationship with PCP, hospital, other providers

Attorney, legal counsel

Utilize, promote consumer organizations



Palliative Care & Hospice

Palliative Care & Hospice

Enhancing the Patient Experience

- Patients often confuse "palliative care" with "hospice"
- Both involve treatment of symptoms often associated with Cancer to improve quality of life
 - Pain
 - Gastrointestinal symptoms
 - Challenges getting enough nutrition and hydration
 - A wide range of other symptoms
- Both include caregiver support, including respite care
- Major differences:
 - hospice requires <=6mos. life expectancy
 - Palliative care allows treatment with curative intent – hospice does not
 - Hospice provides strong care coordination for hospice-specific services
 - there is well-defined benefit language for hospice; less so for palliative care

Palliative care... is specialized medical care that focuses on providing patients relief from pain and other symptoms of a serious illness, no matter the diagnosis or stage of disease. Palliative care teams aim to improve the quality of life for both patients and their families. This form of care is offered alongside curative or other treatments you may be receiving. [Source: Mayo Clinic]

Hospice care... is a special kind of care that focuses on the quality of life for people and their caregivers who are experiencing an advanced, life-limiting illness. Hospice care provides compassionate care for people in the last phases of incurable disease so that they may live as fully and comfortably as possible. [Source: American Cancer Society]



Palliative Care & Hospice

Differences in Scope of Benefits

Most health plans offer hospice benefits patterned on the Medicare Hospice Benefit

- May limit # days
- Typically contracts per diem % of Medicare

No standard "Palliative Care Benefit" per se:

- Medicare pays for elements of palliative care that it covers individually
- Typical employment-based plans cover services, when taken together can make up palliative care

Example of Hospice Benefits (Medicare) In home or an inpatient facility...

- Doctor services
- Nursing care
- Medical equipment (like wheelchairs or walkers)
- Medical supplies (like bandages and catheters)
- Prescription drugs
- Hospice aide and homemaker services
- Physical and occupational therapy
- Speech-language pathology services
- Social worker services
- Dietary counseling
- Grief and loss counseling for you and your family
- Short-term inpatient care (for pain and symptom management)
- Short-term respite care
- Any other Medicare-covered services needed to manage your terminal illness and related conditions, as recommended by your hospice team

Source: CMS Medicare Hospice Benefits



Palliative Care & Hospice

Enhancing Quality of Life Near the End of Life

How palliative care and hospice can help

- Managing symptoms physical & mental
- Providing information about changes one might experience as the illness progresses
- Guiding families in giving care and support to their loved one
- Offering emotional support to individuals and their families
- Preventing hospitalizations with a nurse available any time, day or night
- Making bereavement support available to families in a variety of ways

When is hospice is brought up for discussion:

- When the doctor says there are no more treatments
- Second line: case manager might bring it up
- When the patient says "I'm done"



PATIENT RESOURCES

Four Key Differences Between Hospice and Palliative Care

- Hospice requires less than six months life expectancy; palliative care does not.
- Palliative care allows treatment with curative intent; hospice does not.
- Hospice provides strong care coordination for hospice-specific services.
- There is well-defined benefit language for hospice, but less so for palliative care.





WHAT PURCHASERS SHOULD DO

Palliative Care & Hospice

- Educate your work force about Palliative & Hospice Care
- With your health plan:
 - Formulate a palliative care benefit; or
 - Identify existing covered benefits that can make up a palliative care approach
- Make sure:
 - Your health plans cover Palliative & Hospice Care, including caregiver support
 - Your health plans cover Palliative & Hospice Care providers in their networks
 - High-quality palliative care services are offered to cancer patients as early as possible by the treating physician, cancer center, or health plan
- Require health plans to collect data* on events near the end of life including:
 - ER visits by cancer patients enrolled in hospice
 - Proportion in hospice for less than three days

Aetna's Compassionate Care Program

Among commercial health plan members, the program led to a more than doubling in hospice use as well as an increase in hospice lengths of stay (13 to 15 days longer). Extending hospice benefits to 12 months did not result in increased costs compared to those without extended hospice benefits.

Source:

https://www.commonwealthfund.org/publications /case-study/2018/may/profiles-promise-advancedillness-management

*Source: Core Quality Measures, Developed by the Core Quality Measures Collaborative, led by the America's Health Insurance Plans (AHIP) and its member plans' Chief Medical Officers, leaders from CMS and the National Quality Forum (NQF), as well as national physician organizations, employers and consumers.

POLL THE AUDIENCE

- 3) Palliative Care & Hospice Which of the following does your organization have in place?
- **Palliative Care & Hospice education to all employees**
- **Identify or formulate a palliative care benefit with health plan(s)**
- Ensure health plan(s) cover palliative care and hospice, including caregiver support, and providers of these services within network
- High-quality palliative care offered to cancer patients as early as possible by treating physician, care center, or health plan
- Require health plan to collect data on events near end of life including ER visits and proportion of hospice less than 3 days





Advance Care Planning, Palliative Care & Hospice

Question Prompts for Facilitated Roundtable Discussion

- 1. How can employers best engage their workforce around advance care planning? How deep into the issue should they go?
- 2. How can employers reach population segments with different cultures, expectations and attitudes about Advance Care Planning?
- 3. How can we best confirm that health plans offer robust palliative care benefits?
- 4. Measuring the appropriate use of hospice care can require capturing the "date of death," for example, to monitor whether hospice patients actually spend a good bit of time in hospice or enroll within days of death. How can employers or their health plans capture this information?





Survivorship, Surveillance & Back-to-Work

Survivorship, Surveillance & Return to Work

Growth in Survivorship \rightarrow New Demands on Employers

Cancer survivorship is projected to increase by 25% to 30% during the 10 years ending in 2026

As a result, employers will find that more of their employees:

- Need to adhere to periodic surveillance protocols
- Are caregivers for others with cancer
- Can benefit from survivorship plans

These trends cause new, increasing demands on employers





Survivorship, Surveillance & Return to Work Identify New Roles for EAP or Seek Support from Outside Agencies

Training & seminars

- Prevention, Screening & Advance Planning for entire workforce – before the Patient Journey
- Worksite accommodation during and after Patient Journey
- Awareness of disability coverage

Intake & referral (if not otherwise provided by provider or health plan), e.g.,

- Psychosocial, navigational, financial, other support during Patient Journey
- Specialized services CoE, hospice

Support for challenging cases

Employees (& families) facing bad outcomes

Support managers addressing employees' needs, including survivorship & return to work





Increasing Survivorship Drives Increase in Need for Surveillance

Employers Should Develop a Value-Based Approach

Projected Number of Cancer Survivors by Tumor Site (2016-2026)*

As of Jan	uary 1, 2016
Male	F
Prostate 3,306,760	3,
Colon & rectum	Uter
724,690	7
Melanoma	Color
614,460	7
Urinary bladder	T
574,250	6
Non-Hodgkin lymphoma	Me
361,480	6
Kidney & renal pelvis 305,340	Non-Hod
Testis	Lung
266,550	2
Lung & bronchus	Uter
238,300	2
Leukemia 230,920	2
Oral cavity & pharynx	Kidney
229,880	2
Total survivors	Total
7,377,100	8,

Female Breast 3,560,570 Uterine corpus 757,190 Colon & rectum 727,350 Thyroid 630,660 Melanoma 612,790 Non-Hodgkin lymphoma 324,890 Lung & bronchus 288,210 Uterine cervix 282,780 Ovary 235,200 Kidney & renal pelvis 204,040 **Total survivors** 8,156,120

As of January 1, 2026

Male Prostate 4,521,910 Colon & rectum 910,190 Melanoma 848.020 Urinary bladder 754,280 Non-Hodgkin lymphoma 488,780 Kidney 429,010 Testis 335,790 Leukemia 318,430 Lung & bronchus 303,380 Oral cavity & pharynx 293,290 **Total survivors** 9,983,900

Female Breast 4,571,210 Uterine corpus 942,670 Colon & rectum 885,940 Thyroid 885,590 Melanoma 811,490 Non-Hodgkin lymphoma 436,370 Lung & bronchus 369,990 Uterine cervix 286,300 Kidney & renal pelvis 284,380 Ovary 280,940 **Total survivors** 10,305,870

*Source: MD Anderson Cancer Center



National Alliance- PCORI Engagement (2019)

Cross-National Study of Colorectal Cancer Surveillance

Study found:

Intensification of surveillance has a negligible impact on the detection of recurrence or survival

- May slightly increase rate surgery for distant recurrence
- No need to image more frequently than once/year
- Earlier stage patients may require less follow-up

Follow-up care should emphasize

- Management of treatment associated toxicity
- Health promotion and secondary prevention
- Psychosocial well-being

E SURVEILLANCE
oncer survivors be monitored for disease recurrence?
What's the leases! There are 0.5, values save contents in the indeed lease and receiver coperated to in 0.5, values in 0.05. Boy to every locate source uses paid to the regime rests will be reconcerned to their coperation are list of the source indeed
counteners can arbod lang-core touth air op pains of 46. These proving painsker residencicians take a langton index on encopyer's mattrace core, approxima to posicioner core policia, and workloop wellings
Rates Realized Marcine
What did the PD/081-Austical starks dot The publicities focuses on event being-time a local publicities by the Values Construct Construct Construct Construct Construct Testing foremary products of biology agery for schematic Construct Automation testing foremary products of the public construction of the public construction testing foremary products of the public construction testing foremary public construction testing testing foremary public construction testing testing foremary public construction
What were the results and their potential impact?
Design / Chorps Alls, VE, The Allence (in Chernel Verille Chernley Foundation With A course particle Verill Foreign and and an

"This PCORI-funded study found that healthcare facilities that do more frequent surveillance did not detect recurring cancers any earlier than facilities that do less frequent surveillance, suggesting more frequent testing provided no health benefit."

George J. Chang, MD, MS; The Alliance for Clinical Trials in Oncology Foundation



Increasing Demands on Caregivers can Impact Employers Needs Often Ignored

Employees who are the patient may require support from family or other caregivers

Employees may be caregivers and require time off to fulfill this role

Work accommodations for caregivers

- Telecommuting
- Flex time
- Use of sick time and other paid and unpaid time off

It is important for the patient and caregiver to have access to as much support as possible

- Educational materials
- Financial support
- Care coordination
- Clear understanding of the benefits available through all benefit lines medical, behavioral health, EAP, specialty vendors

Checklist of Caregiver Needs

- Identify wide range of friends and others who can help with these services
- Identify services available through employer programs such as EAP
- Use respite services if available
 - o Home health aid
 - Respite care facility
 - Private duty nurse



PATIENT RESOURCES



Checklist of Resources for Caregivers

- Identify wide range of friends and others who can help.
- Identify services available through employer programs such as EAP.
- Use respite services if available:
 - Home health aid.
 - Respite care facility.
 - Private duty nurse.



WHAT PURCHASERS SHOULD DO

Planning for Increased Survivorship

Plan for the impact of increased cancer survivorship on their organization:

- Develop support resources, whether EAP or external organizations, specifically to:
 - Support appropriate surveillance adherence
 - Consider the needs of employee caregivers
- Encourage Survivorship Planning

Sources:

OncoLink: https://oncolife.oncolink.org/

ASCO: <u>https://www.cancer.net/survivorship/follow-care-after-cancer-treatment/asco-</u> cancer-treatment-and-survivorship-care-plans

			61	D TM		
	Sur	Nivorship Car	e Plan Reni	Feedback OncoLi	nk	
HCP FAQS	Survivor FAQs References	Publications	Editoria		6	7
4	2	3	4 Surgeries	5 Chemoliterapy and Biologic Therapiee	Papiation Therapy	Side Ethecis
		Cancer Types				
Care elan Ven	eion Demographics					
Care Plan Ven	Cancer Type/Location/Histology Stage I III III IV II	Ti Subtype: Prostate C	teatment Summary Diagnosis Cancer	Diamont		
Care Plan Ver	Cancer Type/Location/Histology Stage Gleason Score. Clinical Trial:YesNo Name	T Subtype: Prostate (Not applicable s/Number:	Cancer PSA at Diagno	Diagnosis Date	: (year):	
Care elan ver	Cancer Type/Location/Histology Stage I III III IV II	T Subtype: Prostate (Not applicable s/Number:	itestment Summary Diagnosis ancer PSA at Diagno atment Completed Surgery Date(s	sis:	(year):	
H	Cancer Type/Location/Histology Stage Gleason Score. Clinical Trial:YesNo Name	I Subtype: Prostate (O Not applicable //Number: //Number: //Number: //Number: //Number:	Ancer PSA at Diagno PSA at Diagno atment Completed Surgery Date(s strment Ongoing Yrs D + +++++++++++++++++++++++++++++++++	sis:	(year):	
H	Cancer Type/Location/Histology Stage Gleason Score Dinical Trial Yes No Name Surgery:	I Subtype: Prostate (O Not applicable //Number: //Number: //Number: //Number: //Number:	Ancer PSA at Diagno atment Completed Surgery Date(s	sis:		
H	Cancer Type/Location/Histology Stage Gleason Score Dinical Trial Yes No Name Surgery:	Tres	Comprode Ancer PSA at Diagno PSA at Diagno Atment Completed Surgery Date(s Surg) (year): Possible Side eff		
H	Cancer Type/Location/Histology Stage:in In Ir / Ginical Trial: Yes No Name Surgery: Need for ongoing (adjuvant) treatm Additional treatment name Coordinating Provider	Tree Subtype: Prostate (Not applicable e/Number: Tree ent for cancer Pla Follow Schedule	Ancer Ancer PSA at Diagnode atment Completed Surgery Date(s atment Ongoing atment Ongoing atment Ongoing atment duration where duration atment duration where the of Clinical Visits When) (year): Possible Side eff		
H	Cancer Type/Location/Histology Stage:in In Ir / Ginical Trial: Yes No Name Surgery: Need for ongoing (adjuvant) treatm Additional treatment name Coordinating Provider	Tree Subtype: Prostate of Not applicable Not applicable Number: Tree Tree Follow Follo	Ancer PSA at Diagnod PSA at Diagno PSA at Diagno atment Completed surgery Date(s surgery) (year): Possible Side eff		
H	Cancer Type/Location/Histology Stage:in In Ir / Ginical Trial: Yes No Name Surgery: Need for ongoing (adjuvant) treatm Additional treatment name Coordinating Provider	Tree Subtype: Prostate of Not applicable Not applicable Number: Tree Tree Follow Follo	Comprode Ancer PSA at Diagno PSA at Diagno Atment Completed Surgery Date(s Surg) (year): Possible Side eff		

POLL THE AUDIENCE

4) Survivorship – Does your organization have a plan in place for the impact of increased cancer survivorship on your organization?

□Yes, we have a plan

No, but we are working on a plan

No, we do not have a plan at this time





Survivorship, Surveillance Return to Work

Question Prompts for Facilitated Roundtable Discussion

- 1. Has your organization noticed an increase in cancer survivors and, if so, what has been the impact?
- 2. What are your thoughts about treating employees who are caregivers with some of the same flexibility as you treat employees undergoing cancer treatment?
- 3. What has been your organization's experience with EAP providing support to cancer patients or caregivers who are in your active workforce?
- 4. How would you go about introducing the idea of survivorship planning to your employees?





Payment Reform

Discussion of Payment Reform

Progress has been Slow

There have been attempts to reform payment based on bundled payment

These have largely failed for a number of reasons:

- The incidence of cancers is fairly low. For example, there are about 280,000 cases of breast cancer (the most common cancer) predicted for 2020. That's about 1 per every 1100 population.
- The severity of the disease within a cancer type can vary markedly.
- The prevalence of any specific cancer in a population is relatively small
- Prognosis and therapy varies by the patient's underlying risk factors and other conditions
- Over the past few years there has been rapid development of biomarkers and biomarker specific therapies. These may affect a small percentage of patients but can drive much higher costs.
- The diagnosis of cancer raises emotional concerns and demand for more flexibility in the choice of treatment center. This makes managing volume commitments to a specific center more difficult.

Bottom line – the relatively low incidence, the complexity of the disease, and the variation in treatments makes the usual payment reform methods unworkable.

Extension of care over a period longer than one-year term of health insurance can also be a challenge





20

Medicare Oncology Payment Model (OPM)

Begun in 2016 as a 5-year CMS Innovation Center Program

Based on FFS program with additional payment for enhanced services

- The core functions of patient navigation;
- A care plan that contains the 13 components in the Institute of Medicine Care Management Plan outlined in the Institute of Medicine report, "Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis";
- Patient access 24 hours a day, 7 days a week to an appropriate clinician who has real-time access to practice's medical records; and
- Treatment with therapies consistent with nationally recognized clinical guidelines.

Sets quality standards

The Performance-Based Payment was calculated retrospectively on a semi-annual basis based on the practice's achievement on the OCM Quality Measures and reductions in Medicare expenditures below a target price.

https://www.cms.gov/newsroom/fact-sheets/oncology-care-model





Medicare Oncology Payment Model (OPM) Year 3 Report

Financial

- No significant impact on overall payment
- Net loss to Medicare when payment for enhanced services are included
- No reductions in use of novel treatments
- No increase in efficiency

Quality

- Improved care coordination with 24/7 access
- Expanded financial counseling
- No change in ER visits or hospital admissions
- No change in chemotherapy toxicity events
- 1.1% decrease in hospital admissions at the end of life

Bottom line "Little Evidence of Value-Oriented Changes in Therapeutic Approach. There is little evidence that OPM is driving value-oriented selection of chemotherapy regimens, supportive care medications, or radiation therapy treatment. "

https://innovation.cms.gov/data-and-reports/2020/ocm-evaluation-annual-report-2





Payment Innovation Initial Steps

While payment methods for other conditions such as care bundles or capitation may not be feasible for cancer there are other tactics that can manage expense

- Bundle chemotherapy costs to include the drug, infusion and site of care costs
- Value Based Pharmacy, especially for the newer high-cost drugs
- Steer patients and/or require the use of lower cost care centers such as outpatient infusions or even home infusions where appropriate
- Identify high value providers
 - Adhere to standard guidelines
 - Provide care in the most efficient settings
 - Provide care navigation and coordination
 - Provide comprehensive support for patients and families

Overall, value-based contracting for biopharmaceuticals is in its early stages, and the consensus among expert panels convened by NEHI is that thoughtful experimentation in these contracts should proceed.

Source: https://www.nehi.net/publications/79value-based-contracting-for-oncology-drugs-anehi-white-paper/view



Cancer Characteristics Limit Use of Most Payment Reform Methods

- Low incidence, e.g., breast cancer incidence is 1.3/1,000.*
- The prevalence of any specific cancer is also low.
- The severity within a cancer type can vary markedly.
- Prognosis and therapy vary by patient's risk factors and comorbidities.

- Rapid development of biomarkers and biomarker specific therapies affect a smaller percentage of patients but can drive much higher costs.
- Patients' emotional concerns and demand for more flexibility in selection of treatment center makes managing volume commitments to a specific center more difficult.

Source: https://seer.cancer.gov/statfacts/html/ breast.html



HIGH VALUE CANCER PROVIDERS:

Adhere to standard guidelines.

- Provide care in the most efficient settings.
- Provide care navigation and coordination.

Provide comprehensive support for patients and families.





POLL THE AUDIENCE

5) Payment Reform – Is your organization utilizing or considering bundled payments for oncology or other conditions?

Yes, we currently have bundled payment arrangements
No, but we are considering and/or would like more information
No, we are not interested at this time





Payment Reform and Innovation


Question Prompts for Facilitated Roundtable Discussion

- 1. Does your health plan have any bundled payment arrangement or other alternative payments for cancer care?
- 2. Does your plan identify the high value cancer care providers or centers?
- 3. How do you feel about using incentives for employees to use high value cancer providers? Is it different for cancer than other conditions?
- 4. If you have separate contracts for your health plan, PBM and specialty PBM, who is responsible for coordinating care and payment?





Impact of COVID-19





Impact of COVID-19 Prevention, A Mixed Bag

Social isolation has given people more time for video tools

- Education/advice for prevention
- Treatment for risk factor: diet, smoking, alcohol

Isolation and stress increase risk may increase risky behaviors and limit positive ones

- Smoking
- Alcohol use increase
- Lifestyle changes more challenging
- Healthy food choices
 - Could go either way decreased restaurant food, but more canned and frozen foods and other foods that may have high salt and fat
 - Exercise may be up despite restrictions on gyms and being outdoors
- Weight loss

Employers for Healthcare Value Since 1980

Unintended Consequences?

The virus has caused so many changes in our daily lives. ...

...might this offer an opportunity to change some habits for the better: eating, exercise, etc.?

Impact of COVID-19 Screening

Concerns about virus exposure limit screening such as mammography, skin exams, pap smears.

Colon cancer screening deferred because of risks to providers and patients.

Cancer screening down 86-94% based on data from Epic

 Worth noting that screening schedules are set on an annual or greater periodicity, so delays of months will probably have little effect on overall rates once the backlog can be processed In response to the coronavirus disease 2019 (COVID-19) pandemic, the U.S. Surgeon General advised all hospitals and ambulatory care centers to delay nonurgent medical procedures and surgeries. ...gastroenterologists, patient advocates, and colorectal cancer (CRC) researchers have witnessed the downstream impact of COVID-19 and this recommendation on CRC screening, research, and advocacy.

These effects are particularly noticeable in medically underserved communities where CRC morbidity and mortality are highest. COVID-19–related pauses in medical care, as well as shifts in resource allocation and workforce deployment, threaten decades worth of work to improve CRC disparities in medically underserved populations.

Source: Gastrointest Endosc 2020;-:1-5.



Impact of COVID-19 Treatment

- Current or past patients with cancer are at increased risk from the virus.
- Treatments (surgery, chemotherapy, radiation) increase risk by decreasing the immune response.
- Social distancing for most cancer care is impossible infusions, surgery, etc.
- The priority for care of COVID patients has limited the availability of beds, operating rooms, ventilators, personal protective equipment and other resources necessary for the care of some patients and the protection of the cancer care staff.

According to Flatiron Health's analysis of medical record data:

- 13% fewer scheduled chemotherapy infusion visits were fulfilled
- 33% drop in daily non-infusion visits
- 60% increase in appointment cancellations
- 50% decrease in new patient visits



Impact of COVID-19

Treatment (continued)

Not all cancer types or clinical picture pose the same acute risk.

- Treatment for many conditions can be safely delayed for a few months with very low risk.
- Specialty societies have developed recommendations for treatment based on which tumor types and findings need acute care and which can wait with minimal risk

In addition to the risk stratification and risk-benefit issues, local conditions need to be taken into consideration:

- Where in the course of epidemic is the location?
- Are there beds available for all acute care?
- Is there adequate PPE, etc.?





Impact of COVID-19 Treatment (cont.)

Case Study (Netherlands): Changes to treatment processes

5,302 patients with cancer completed this nationwide survey

- Overall, 30% of patients reported consequences for their oncological treatment or follow up.
- Most common was a switch from in person to video visits.
- The most frequently adjusted treatments were chemotherapy (30%) and immunotherapy (32%).
- Among patients with delay and discontinuation of treatment, 55% and 63% of patients, respectively, were (very) concerned about these consequences of theCOVID-19 pandemic





COVID-19 impact on future cancer deaths

Another study (UK): increased mortality

A study of 32,583 patients with breast cancer, 24,975 with colorectal cancer, 6,744 with esophageal cancer, and 29,305 with lung cancer developed three different scenarios, compared with pre-pandemic figures and estimated an increase in deaths over 5 years for a number of cancers.

Type of Cancer	Increase in Deaths	
Breast	+7.9–9.6%	
Lung	+4.8-5.3%	
Esophageal	+5.8-6.0%	

Source: Lancet Oncol 2020; 21: 1023–34, Published Online, July 20, 2020, https://doi.org/10.1016/S1470-2045(20)30388-0





Impact of COVID-19

Clinical Trials

All of the challenges for care apply to clinical trials with additional constraints

- Clinical trials of treatment other than oral medication require travel to a health care facility. There may be perceived and actual risks of doing so.
- Clinical trials require monitoring on a set schedule. Patients may be concerned about having imaging or blood tests.
- Delays in patient evaluation may threaten the validity and acceptability of the trial.
- Recruitment may be a challenge with the lack of face-to-face discussions.

Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic





Impact of COVID-19: Forcing change

Covid presented an opportunity for innovative service delivery

In order to avoid exposure to Coronavirus, more care has had to be delivered virtually. This has opened up new opportunities for more efficient care after the pandemic.

Assessment for initial care as well as for follow up can be partially completed virtually

- Evaluation of symptoms and even visual inspection of masses
- Review of previous testing
 - Testing and imaging must be performed in person but can be done at sites with limited exposure risk.
- Risk stratification, assessment of urgency and treatment planning
- Tumor boards

Treatment at home can often be done safely, even some infusions.

While most oncologists had not previously used virtual services, the current situation has resulted in significantly increased use.

The Moffitt cancer center (Tampa, Florida NCI Comprehensive Cancer Center) has increased virtual visits 5,000%.

https://www.pennmedicine.org/updates/blogs/penn-physicianblog/2020/june/infusion-therapy-and-home-based-chemo-theinnovation-of-penn-cancer-care-at-home

https://www.cancer.org/treatment/treatments-and-sideeffects/planning-managing/getting-treatment-at-home.html



Impact of COVID-19

Question Prompts for Facilitated Roundtable Discussion

- 1. How has Covid affected your employees' access to care?
- 2. Have the providers in your community offered alternatives to in-person care? If so, what has worked and what has been challenging?
- 3. Have you seen a change in your volume or cost of claims?
- 4. How have you or your providers help employees get access to preventive and follow up care?
- 5. What are the employer communications implications?





Summary of Key Takeaways

What Employers Should Look For From Their Plans

ADVANCE CARE PLANNING – assistance & resources

PALLIATIVE CARE & HOSPICE – education, benefit coverage & data collection

PLAN FOR INCREASED SURVIVORSHIP – and caregiver support

PAYMENT REFORM – bundles, lower cost care & high-quality providers

IMPACT OF COVID-19 – innovative service delivery opportunities



POLL THE AUDIENCE

6) Key Takeaways – Based on today's module, which area is the priority area for your organization?

- **Advance care planning**
- **Palliative care & hospice**
- □Planning for increased survivorship
- **D**Payment reform
- □Impact of COVID-19 throughout the cancer patient journey






ROUNDTABLE DISCUSSION

Module 3: Employer Feedback & Reflection

- 3 key takeaways?
- Greatest opportunity for increasing value?
- How can you better work with your health plan to take advantage of these opportunities?
- Specific points that will create a difference in seeking better care for your members?
- What additional information would you like about this portion of the patient journey?





THANK YOU!

Contact Information:

Amanda Greene

agreene@lvbch.com

LVBCH • 60 West Broad Street, Suite 306 • Bethlehem, PA 18018 • (610) 317-0130 • lvbch@lvbch.com



Glossary

Term	Definition (Source)
Advance Directive	A legal document containing written instructions about your future medical care if you become unable to speak for yourself. (1)
Advance Care Planning	Advance care planning is making decisions about the healthcare you would want to receive if you're facing a medical crisis. These are your decisions to make based on your personal values, preferences, and discussions with your loved ones. (2)
AHIP	America's Health Insurance Plans
AHQR	Agency for Healthcare Quality & Research
American Society of Clinical Oncology (ASCO)	Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. (3)
Approved off-label Rx	 [Approval of] The use of a medication for a purpose other than the use approved by the U.S. Food and Drug Administration (FDA). The FDA approves drugs as safe and effective for specific uses, for example, use for colon cancer or breast cancer. More than half of the uses of anticancer medications are for indications which are not specified as approved and indicated on the label. Some insurance companies may deny coverage for a medication that is used "off-label." The federal government requires that Medicare cover these off-label uses for treating life-threatening conditions as long as certain requirements are met. This is true for many private insurers as well. (1)
ASCO	American Society of Clinical Oncology
Biomarker	A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule. (4)
Biomarker Testing	Also called tumor profiling, genomic testing, mutation testing, or molecular testing. Looks for changes in the cancer's genes. Helps your doctor match targeted therapies to the specific subtype of cancer you have. A sample of your cancer is collected via bodily fluids, surgery, or biopsy and sent to a lab. Your test results can then be used to help guide your treatment options. For example, your biomarker test results will show if you're ALK+ in lung cancer, HER2+ in breast cancer, or BRAF+ in melanoma or colorectal cancer. (1)



Definition (Source)
Consumer Assessment of Healthcare Providers and Systems
The extent of cancer in the body, including whether the disease has spread from the original site to other body sites. (1)
Treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy may be given by mouth, injection, or infusion, or on the skin, depending on the type and stage of the cancer being treated. It may be given alone or with other treatments, such as surgery, radiation therapy, or biologic therapy. (4)
Clinical pathways—also referred to as "treatment pathways," "patient pathways," or simply "pathways"—are multidisciplinary plans of best clinical practices. In some respects, clinical pathways can be viewed as algorithms, outlining the sequence of treatment decisions to be made and the care to be provided for a given patient in a given condition. (5)
Guidelines developed to help health care professionals and patients make decisions about screening, prevention, or treatment of a specific health condition. (4)
Treatments that are used along with standard medical treatments but are not considered to be standard treatments. One example is using acupuncture to help lessen some side effects of cancer treatment (4)
A cancer research center that gets support from the National Cancer Institute (NCI) to do cancer research and provide services directly to cancer patients. Scientists and doctors at these centers do basic laboratory research and clinical trials, and they study the patterns, causes, and control of cancer in groups of people. Also, they take part in multicenter clinical trials, which enroll patients from many parts of the country. Comprehensive Cancer Centers also give cancer information to health care professionals and the public. More information about the NCI Cancer Centers Program can be found on the NCI's Web site at http://cancercenters.cancer.gov. (4)





Term	Definition (Source)
Disparities	Health and health care disparities refer to differences in health and health care between groups. A "health disparity" refers to a higher burden of illness, injury, disability, or mortality experienced by one group relative to another.1A "health care disparity" typically refers to differences between groups in health insurance coverage, access to and use of care, and quality of care. Health and health care disparities often refer to differences that are not explained by variations in health needs, patient preferences, or treatment recommendations and are closely linked with social, economic, and/or environmental disadvantage. The terms "health inequality" and "inequity" also are used to refer to disparities (6)
Dosimetrist	A medical dosimetrist is an analytical member of the radiation oncology team who works closely in collaboration with the radiation therapists, medical physicists, and radiation oncologists within the department. A medical dosimetrist has an overall knowledge of math, physics, anatomy & physiology, radiobiology, and knows the characteristics and clinical relevance of radiation oncology treatment machines and equipment. With their expertise, medical dosimetrists design, generate, and measure radiation dose distributions and dose calculations while providing oversight to high level treatment procedures in both external beam radiation therapy and brachytherapy. (7)
Genetic Counseling	A communication process between a specially trained health professional and a person concerned about the genetic risk of disæse. The person's family and personal medical history may be discussed, and counseling may lead to genetic testing. (4)
Genetic Marker	A genetic marker is a DNA sequence with a known physical location on a chromosome. Genetic markers can help link an inherited disease with the responsible gene. (8)
Genomic testing	See "biomarker testing."
Hospice	A program that gives special care to people who are near the end of life and have stopped treatment to cure or control their disease. Hospice offers physical, emotional, social, and spiritual support for patients and their families. The main goal of hospice care is to control pain and other symptoms of illness so patients can be as comfortable and alert as possible. It is usually given at home, but may also be given in a hospice center, hospital, or nursing home. (4)
Integrative Medicine	A type of medical care that combines conventional (standard) medical treatment with complementary and alternative (CAM) therapies that have been shown to be safe and to work. CAM therapies treat the mind, body, and spirit. (4)



Term	Definition (Source)
Mutation	A gene mutation is a permanent alteration in the DNA sequence that makes up a gene, such that the sequence differs from what is found in most people. (9)
National Cancer Institute	The National Cancer Institute, part of the National Institutes of Health of the United States Department of Health and Human Services, is the Federal Government's principal agency for cancer research. The National Cancer Institute conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Access the National Cancer Institute Web site at http://www.cancer.gov. Also called NCI.(4)
NCCN	The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education. A listing of member institutions can be found at: https://www.nccn.org/members/network.aspx (10)
NCI	National Cancer Institute
NCI-designated centers	Cancer centers designated by the The National Cancer Institute (NCI), The NCI is part of the National Institutes of Health of the United States Department of Health and Human Services, is the Federal Government's principal agency for cancer research. The National Cancer Institute conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Access the National Cancer Institute Website at http://www.cancer.gov. Also called NCI. Source: https://www.cancer.gov/publications/dictionaries/cancer-terms/
NCQA	National Committee for Quality Assurance
NIH	National Institutes of Health





Term	Definition (Source)
Oncology PCMH	 NCQA has retired the Oncology Medical Home Recognition Program effective October 25, 2019. Practices that have already earned recognition will maintain their status through their expiration date. For a listing of the oncology practices that were pioneers of this program, visit the NCQA Report Cards. Practices that were planning on pursuing NCQA Oncology Medical Home Recognition should instead pursue Patient-Centered Specialty Practice (PCSP) Recognition. The PCSP Recognition program builds on Patient-Centered Medical Home (PCMH) Recognition program by recognizing specialty practices that excel in delivering high-quality, patient-centered care. It focuses on proactive coordination and sharing information where everyone in the practice works as a team to coordinate care with primary care, other referring clinicians, community resources and secondary services. The Oncology Medical Home Recognition program featured 7 standards area. The first 6 standards areas are the same standards that are a part of the PCSP Recognition Program. If you were preparing for Oncology Medical Home Recognition, you are already well-positioned to meet PCSP Recognition criteria. (11)
Palliative Care	A medical specialty that focuses on symptom management and quality of life. (1)
Palliative Care	Treatment that relieves symptoms, such as pain, but is not expected to cure disease. Curative treatment can be used at the same time as palliative treatment, but the main purpose of palliative care is to improve the patient's quality of life. (12)
Placebo	An inactive substance, sometimes called a "sugar pill." Placebos are almost never used in cancer clinical trials. Most studies involve getting the standard of care for the specific cancer type. (1)
Precision Medicine	A process to find the best treatments for each specific patient based on exact gene changes or proteins in their cancer. Your doctors test for biomarkers, cell changes (mutations), or other targets found in/on your cancer cells. Then treatments are offered that target the specific biomarker or mutation found in your cancer. These "targeted" drugs are expected to work better. Sometimes called personalized medicine. (1)
QCP	Quality Oncology Practice Initiative (QOPI®) Certified Practice
QOPI	Quality Oncology Practice Initiative





Term	Definition (Source)
Radiation Therapy	The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy or brachytherapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body. Also called irradiation and radiotherapy. (4)
Shared Decision Making	In medicine, a process in which both the patient and healthcare professional work together to decide the best plan of care for the patient. When making a shared decision, the patient's values, goals, and concerns are considered. Shared decision making helps patients learn more about their health condition, the different testing and treatment options that may be available, and the possible risks and benefits of each option. It is often used when important medical decisions need to be made, such as about having a genetic test or cancer screening test, having major surgery, or taking a medicine over a long time. (4)
Survivorship	In cancer, survivorship focuses on the health and well-being of a person with cancer from the time of diagnosis until the end of life. This includes the physical, mental, emotional, social, and financial effects of cancer that begin at diagnosis and continue through treatment and beyond. The survivorship experience also includes issues related to follow-up care (including regular health and wellness checkups), late effects of treatment, cancer recurrence, second cancers, and quality of life. Family members, friends, and caregivers are also considered part of the survivorship experience. (4)
Survivorship Care Plan	A detailed plan given to a patient after treatment ends, that contains a summary of the patient's treatment, along with recommendations for follow-up care. In cancer, the plan is based on the type of cancer and the treatment the patient received. A survivorship care plan may include schedules for physical exams and medical tests to see if the cancer has come back or spread to other parts of the body. Getting follow-up care also helps check for health problems that may occur months or years after treatment ends, including other types of cancer. A survivorship care plan may also include information to help meet the emotional, social, legal, and financial needs of the patient. It may include referrals to specialists and recommendations for a healthy lifestyle, such as changes in diet and exercise and quitting smoking. Also called follow-up care plan. (4)





Term	Definition (Source)
Targeted therapy	Drugs that target specific cellular pathways that enable cancer cells to grow. (1)
Tumor Board Review	A treatment planning approach in which a number of doctors who are experts in different specialties (disciplines) review and discuss the medical condition and treatment options of a patient. In cancer treatment, a tumor board review may include that of a medical oncologist (who provides cancer treatment with drugs), a surgical oncologist (who provides cancer treatment with surgery), and a radiation oncologist (who provides cancer treatment treatment with redication). Also called multidisciplinary opinion. (4)
Tumor Board Review	A treatment planning approach in which a number of doctors who are experts in different specialties (disciplines) review and discuss the medical condition and treatment options of a patient. In cancer treatment, a tumor board review may include that of a medical oncologist (who provides cancer treatment with drugs), a surgical oncologist (who provides cancer treatment with surgery), and a radiation oncologist (who provides cancer treatment with radiation). Also called multidisciplinary opinion. (4)
United States Preventive Services Task Force (USPTF)	The U.S. Preventive Services Task Force is an independent, volunteer panel of national experts in disease prevention and evidence- based medicine. The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. (13)
VA	Veterans Administration





Glossary (Sources)

Cancer Support Community (1)(2)www.nhpco.org/patients-and-caregivers/advance-care-planning/ (3)https://www.asco.org/about-asco [Module] (4)www.cancer.gov www.journalofclinicalpathways.com/article/evolution-clinical-pathways-oncology (5) (6)www.kff.org www.medicaldosimetry.org/about/medical-dosimetrist/ (7)(8) www.genome.gov/glossary/index.cfm?id=86 www.ghr.nlm.nih.gov/primer/mutationsanddisorders/genemutation (9) www.nccn.org/about/default.aspx (10)www.ncqa.org/programs/health-care-providers-practices/oncology-medical-home/oncology-medical-home-recognition-program-(11)retirement/ www.cancer.org/cancer/glossary.html (American Cancer Society) (12)(13)www.uspreventiveservicestaskforce.org/





Additional Resources

Advance Care Planning

AARP https://www.aarp.org/caregiving/financial-legal/free-printable-advance-directives/

American Bar Association https://www.americanbar.org/groups/law_aging/resources/health_care_decision_making/cons umer_s_toolkit_for_health_care_advance_planning/

Cancer Support Community <u>https://www.cancersupportcommunity.org/radio-show/spotlight-metastatic-breast-cancer-advanced-care-planning</u>

National Academy of Sciences. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life, 148-154 (2015)

National Hospice and Palliative Care Organization https://www.nhpco.org/





Survivorship Planning

American Society of Clinical Oncology <u>https://www.cancer.net/survivorship/follow-care-after-cancer-treatment/asco-cancer-treatment/asco-cancer-treatment-and-survivorship-care-plans</u>

OncoLink (University of Pennsylvania) https://oncolife.oncolink.org/





References: Impact of COVID-19

- Overall impact: (<u>https://flatiron.com/blog/impact-covid-community/</u>)
- Increased risk of alcohol use: (<u>https://healthcare.utah.edu/the-scope/shows.php?shows=0_p0xim6x3</u>)
- Healthy food choices: (<u>https://time.com/5827315/coronavirus-diet/</u>)
- Exercise: (<u>https://time.com/5827315/coronavirus-diet/</u>)
- Screening: (<u>https://www.cancerhealth.com/article/routine-cancer-screenings-plunge-covid19</u>)
- Assessment: % (<u>https://moffitt.org/for-healthcare-providers/onco-update-provider-blog/onco-update-story-archive/virtual-oncology-visits-are-up-5-000-at-moffitt-are-they-here-to-stay-after-covid-19/</u>)
- Assessment: https://nyulangone.org/news/new-suspicion-cancer-virtual-clinic-provides-consults-peoplewho-may-have-cancer-symptoms





References: Impact of COVID-19 (cont.)

- Annals of Surgical Oncology. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations: (<u>https://link.springer.com/article/10.1245/s10434-020-08461-2</u>)
- Radiation Oncology: (<u>https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/Summary</u>); The Impact of COVID-19 on Radiation Oncology Clinics and Patients With Cancer in the United States: (<u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118653/</u>)
- Clinical Trials: https://clincancerres.aacrjournals.org/content/early/2020/04/18/1078-0432.CCR-20-1364
- The Future: (<u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167574/</u>)





References: Impact of COVID-19 (cont.)

- American Society for Clinical Oncology. ASCO Guidance on Allocation of Scarce Resources During COVID-19 Pandemic: (<u>https://www.asco.org/asco-coronavirus-information/provider-practice-preparedness-covid-19</u>)
- Virtual Tumor Board: (<u>https://igcs.org/covid-19-virtual-tumor-boards/</u>)
- Annals of Internal Medicine. A War on Two Fronts: Cancer Care in the Time of COVID-19: (<u>https://www.acpjournals.org/doi/pdf/10.7326/M20-1133</u>)
- American College of Surgeons. Local Resumption of Elective Surgery Guidance: (<u>https://www.facs.org/-/media/files/covid19/local_resumption_of_elective_surgery_guidance.ashx</u>)



